Phase 2 Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a confirmed advanced or spreading solid tumour cancer that has stopped responding to standard treatments, cannot tolerate standard treatments, or for whom no standard treatment exists (Part 1); or people with a confirmed advanced or spreading solid tumour who would normally be treated with a medicine called nivolumab (240mg every 2 weeks) as standard care (Part 2); or people with confirmed advanced, inoperable, or spreading melanoma (not the eye type) who have previously been treated with a chemotherapy called dacarbazine and for whom no standard treatment now exists (Part 3)
- People with a life expectancy of at least 3 months after starting the study treatment
- People aged 18 years or older at the time of giving consent
- People who are able to give written consent in person to take part in the study
- Women who could potentially become pregnant must have a negative pregnancy test before enrolling
Who may not be able to join:
- People who have an active, uncontrolled bacterial, viral, or fungal infection that requires systemic (whole-body) treatment
- Women who are pregnant, possibly pregnant (as assessed by their doctor), or currently breastfeeding — stopping breastfeeding in order to enrol is also not permitted
- People who are unwilling or unable to follow the procedures required by the study protocol
- People who test positive for HIV antibodies
- People who test positive for hepatitis B surface antigen (a marker of hepatitis B infection)
- People who test positive for hepatitis C virus RNA (a marker of active hepatitis C infection)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +81467-32-9948
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with dose-limiting toxicities (DLTs) (Part 1 and 2); Number of participants with adverse events (AEs) (Part 1 and 2); Number of participants with adverse events of special interest (AESIs) (Part 1 and 2); Number of participants with serious adverse events (SAEs) (Part 1 and 2); Objective response rate (ORR) (Part 3)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.